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A noncoding repeat expansion in the C9orf72 gene is the most common genetic cause of frontotemporal
dementia and amyotrophic lateral sclerosis. In this issue of Neuron, Ash et al. (2013) show that despite being
noncoding the repeats are translated, leading to widespread neuronal aggregates of the translated proteins.Frontotemporal dementia (FTD) and
amyotrophic lateral sclerosis (ALS) are
related neurodegenerative diseases that
share clinical features, neuropathological
findings, and underlying genetic causes.
FTD is the second most common form of
young-onset dementia (Harvey et al.,
2003; Ratnavalli et al., 2002) and is char-
acterized by selective involvement of the
frontal and/or temporal cortices leading
to behavioral changes or language impair-
ment. ALS is clinically characterized by
loss of upper and lower motor neurons
leading to weakness, paralysis, and ulti-
mately death due to respiratory failure.
Both FTD and ALS are neuropathologi-
cally characterized by the presence of
neuronal inclusions containing TDP-43
protein (Neumann et al., 2006). They can
co-occur within a single individual or in
families with genetically inherited FTD/
ALS suggesting they form a disease
spectrum (Lillo and Hodges, 2009). An
expanded hexanucleotide (GGGGCC) re-
peat in a noncoding region of the chromo-
some 9 open reading frame 72 (C9orf72)
gene was recently shown to be the most
common genetic cause of both FTD and
ALS (c9FTD/ALS) (DeJesus-Hernandez
et al., 2011; Renton et al., 2011). The
high frequency of C9orf72 repeat expan-
sion in FTD/ALS has generated great
interest in the underlying disease mecha-
nism, of which several non-mutually ex-
clusive possibilities exist. One potential
disease mechanism is termed RNA gain
of function and is based on evidence
from other diseases caused by large
expansions of noncoding repeats such
as myotonic dystrophy (Cooper et al.,
2009). In these diseases, the repeat RNA
is transcribed but aggregates in the
nucleus in discrete structures termedRNA foci. The RNA foci sequester RNA-
binding proteins and it is loss of these
RNA-binding proteins which ultimately
leads to disease. This mechanism has
been shown to directly cause specific
aspects of the myotonic dystrophy
phenotype (Cooper et al., 2009). In favor
of this mechanism is the presence of
RNA foci in c9FTD/ALS patient neu-
rons (DeJesus-Hernandez et al., 2011).
Another possibility is loss of function of
C9orf72 protein. Although little is known
about C9orf72 protein function, bio-
informatic approaches have recently
shown that it is structurally related to
DENN proteins, a class of GDP/GTP
exchange factors (GEFs) that activate
Rab-GTPases, suggesting it may have a
role in vesicular trafficking (Levine et al.,
2013; Zhang et al., 2012). In support
of the loss-of-function mechanism is
the finding that the level of GGGGCC
repeat-containing transcripts in patient
brain is decreased (DeJesus-Hernandez
et al., 2011; Gijselinck et al., 2012). The
findings reported in this issue of Neuron
by Ash et al. (2013) now raise a third
possibility that newly identified protein
aggregates may have a role in disease
pathogenesis.
Pathological analysis of c9ALS/FTD
cases show that they contain TDP-43-
positive inclusions but could be distin-
guished from other FTD/ALS cases on
the basis that they all exhibit additional
p62- and ubiquilin-positive pathology (Al-
Sarraj et al., 2011; Brettschneider et al.,
2012; Pikkarainen et al., 2010). This addi-
tional pathology is particularly evident
because of the lack of TDP-43 pathology
in the granular cell layer and CA4 subre-
gion of the hippocampal formation and
the granular cell layer of the cerebellum.Neuron 77,Small p62-positive ‘‘star-like’’ neuronal
cytoplasmic inclusions are also observed.
The nature of these TDP-43-negative
inclusions is of great interest given the
insight into neurodegenerative diseases
that has come from the identification of
aggregating proteins. The key findings
from this new study are the identification
of novel aggregating proteins and their
remarkable specificity for c9ALS/FTD.
Equally intriguing is the mechanism by
which these aggregating proteins are
formed. The proteins are generated by
translation of the expanded non-coding
GGGGCC repeats. Translation occurs
via a recently described phenomenon
termed repeat-associated non-ATG
translation (RAN translation) (Zu et al.,
2011). RAN translation was first shown
for expanded CAG repeats, which cause
a range of neurodegenerative diseases
including Huntington’s disease and sev-
eral spinocerebellar ataxias (Orr and
Zoghbi, 2007). It was clearly demon-
strated in a molecular biology tour de
force that CAG repeat expansions lacking
ATG codons are translated in all three
reading frames, leading to production of
polyglutamine, polyalanine, and polyser-
ine tracts (Zu et al., 2011). RAN translation
was dependent on repeat length as a
minimum of 58 CAG repeats was required
for translation in all three frames. Impor-
tantly, RAN translation products were
observed in protein aggregates in patients
with expanded CAG repeats, confirming
their in vivo relevance (Zu et al., 2011).
Armed with this information Ash et al.
(2013) set out to determine whether
RAN translation occurred in the presence
of the expanded C9orf72 GGGGCC re-
peats. Antibodies were generated by
pooling peptides corresponding to theFebruary 20, 2013 ª2013 Elsevier Inc. 597
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Previewsthree possible reading frames, poly-
(glycine-proline), poly-(glycine-alanine),
and poly-(glycine-arginine). The anti-
bodies generated showed high affinity to
poly-(glycine-proline) with minimal bind-
ing to the other polypeptides and were
termed C9RANT antibodies. Remarkably,
these antibodies revealed the presence of
widespread C9RANT-positive neuronal
aggregates in c9FTD/ALS that were
similar in shape and distribution to the
previously observed p62-positive, TDP-
43-negative inclusions. No staining of
inclusions was observed in 120 cases of
other neurodegenerative diseases, in-
cluding those with TDP-43, Ab, a-synu-
clein, tau, and CAG-repeat pathology,
confirming the specificity of C9RANT to
c9FTD/ALS. The formation of translated
products confirms that the GGGGCC
repeats are transcribed and presumably
transported out of the nucleus for transla-
tion. Importantly, these findings have
been concomitantly reported by other
researchers (Mori et al., 2013a).
These new findings raise a number of
interesting questions. Perhaps the most
important is the disease relevance of the
RAN translation products. The next key
step will be to clarify whether they play
a pathogenic role or are simply innocent
byproducts of the expanded GGGGCC
repeats. It will also be interesting to estab-
lish themechanism bywhich RAN transla-
tion occurs. In the case of CAG repeats,
it was shown to be dependent on the
formation of RNA hairpin structures (Zu
et al., 2011). The recent demonstra-
tion that GGGGCC-repeat RNA forms
G-quadruplexes (Fratta et al., 2012),
a structure shown to have a role in trans-598 Neuron 77, February 20, 2013 ª2013 Elslation initiation (Morris et al., 2010), sug-
gests other mechanisms may also be
possible. Other interesting questions in-
clude the relative contribution of the three
different RAN translation products to neu-
ronal dysfunction, the minimum repeat
length required for GGGGCC RAN trans-
lation to occur in vivo and the mechanism
by which the GGGGCC repeat containing
transcripts exit the nucleus, which could
involve hnRNP A3 (Mori et al., 2013b).
Finally, as the authors propose, the spec-
ificity of the GGGGCC RAN translation
products warrant further investigation
into their utility as potential biomarkers
for c9FTD/ALS.REFERENCES
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